203916-59-0

Basic information

• Product Name: 5-Iodo-2,3,4-trifluorobenzoicacid
• Synonyms: 5-Iodo-2,3,4-trifluorobenzoicacid
• CAS NO: 203916-59-0
• Molecular Formula: C₇H₂F₃IO₂
• Molecular Weight: 301.99
• Mol File: 203916-59-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-Iodo-2,3,4-trifluorobenzoicacid(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Iodo-2,3,4-trifluorobenzoicacid(203916-59-0)
• EPA Substance Registry System: 5-Iodo-2,3,4-trifluorobenzoicacid(203916-59-0)

Safety Data

• Hazardous Substances Data: 203916-59-0(Hazardous Substances Data)

Upstream product

• 124-38-9 carbon dioxide 
• 459425-36-6 2,3,4-trifluoro-1,5-diiodobenzene 
• 1489-53-8 1,2,3-trifluorobenzene 
• 203916-57-8 5-amino-2,3,4-trifluorobenzoic acid 
• 61079-72-9 2,3,4,-trifluorobenzoic acid 
• 459424-72-7 1-iodo-2,3,4-trifluorobenzene 

Downstream Products

• 848852-32-4 2,3,4-trifluoro-5-vinylbenzoic acid 
• 848852-33-5 3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-5-vinylbenzoic acid 
• 848852-34-6 3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-5-formyl-benzoic acid 
• 874100-39-7 3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-5-formyl-N-(2-hydroxyethoxy)benzamide 
• 874100-40-0 5-[1,3]dioxolan-2-yl-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-ethoxy)-benzamide 
• 848851-55-8 C⁽⁵⁸⁰⁾H₄₈₆₀ 
• 848852-36-8 (E)-3,4-difluoro-2-(2-fluoro-4-trimethylsilanylethynyl-phenylamino)-N-(2-hydroxy-ethoxy)-5-[(2-hydroxy-ethoxyimino)-methyl]-benzamide 
• 1313037-46-5 C₁₉H₁₉F₃IN₃O₄S 
• 874100-62-6 3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-ethoxy)-5-(methoxyamino-methyl)-benzamide 
• 874100-89-7 C₂₀H₂₀F₃IN₄O₅ 

Relevant articles and documents

Halogen Bonding Directed Supramolecular Quadruple and Double Helices from Hydrogen-Bonded Arylamide Foldamers

Halogen bonding has been used to glue together hydrogen-bonded short arylamide foldamers to achieve new supramolecular double and quadruple helices in the solid state. Three compounds, which bear a pyridine at one end and either a CF2I or fluor

NOVEL CRYSTAL FORM OF 3,4-DIFLUORO-2-(2-FLUORO-4-IODO-PHENYL AMINO)-N-(2-HYDROXY-ETHOXY)-5-(3-OXO-[1,2]OXAZINAN-2-YLMETHYL)-BENZAMIDE

PROBLEM TO BE SOLVED: To provide an active pharmaceutical ingredient that is useful as MEK inhibitors and is stable physicochemically. SOLUTION: The present invention provides an educt I-type crystal of 3,4-difluoro-2-(2-fluoro-4-iodo-phenyl amino)-n-(2-hydroxy-ethoxy)-5-(3-oxo-[1,2]oxazinan-2-ylmethyl)-benzamide, having peaks with diffraction angles expressed by 2θ of 14.9, 16.9 and 23.1° (±0.2°) in a powder X-ray diffraction pattern measured using Cu Kα(1.54060?) as an X-ray source. SELECTED DRAWING: None COPYRIGHT: (C)2016,JPOandINPIT

Design and synthesis of novel allosteric MEK inhibitor CH4987655 as an orally available anticancer agent

The MAP kinase pathway is one of the most important pathways involved in cell proliferation and differentiation, and its components are promising targets for antitumor drugs. Design and synthesis of a novel MEK inhibitor, based on the 3D-structural information of the target enzyme, and then multidimensional optimization including metabolic stability, physicochemical properties and safety profiles were effectively performed and led to the identification of a clinical candidate for an orally available potent MEK inhibitor, CH4987655, possessing a unique 3-oxo-oxazinane ring structure at the 5-position of the benzamide core structure. CH4987655 exhibits slow dissociation from the MEK enzyme, remarkable in vivo antitumor efficacy both in mono- and combination therapy, desirable metabolic stability, and insignificant MEK inhibition in mouse brain, implying few CNS-related side effects in human. An excellent PK profile and clear target inhibition in PBMC were demonstrated in a healthy volunteer clinical study.

Beyond the MEK-pocket: Can current MEK kinase inhibitors be utilized to synthesize novel type III NCKIs? Does the MEK-pocket exist in kinases other than MEK?

An approach and preliminary results for utilizing legacy MEK inhibitors as templates for a reiterative structural based design and synthesis of novel, type III NCKIs (non-classical kinase inhibitors) is described. Evidence is provided that the MEK-pocket

5-SUBSTITUTED-2-PHENYLAMINO-BENZAMIDE AS MEK INHIBITOR

An objective of the present invention is to provide compounds that exhibit strong MEK-inhibiting activity and are stable in vivo and soluble in water, which can be used as preventive or therapeutic agents for proliferative diseases. The compounds of the present invention and pharmaceutically acceptable salts thereof are represented by the following formula (1): [where R1, R2, R3, R4, and X are the same as defined in the present patent application].

2,3,4-TRIFLUORO-5-SUBSTITUENT-BENZOIC ACID COMPOUND AND PROCESS FOR PRODUCING THE SAME

A 2,3,4-trifluoro-5-substituent-benzoic acid compound represented by the general formula (1): (wherein Y represents iodine, formyl, or an electrophilic species; and M represents hydrogen or a metal); a process for producing the compound; a 2,3,4-trifluoro

PROCESS FOR PRODUCTION OF 2,3,4-TRIFLUORO-5-(IODO OR BROMO)BENZOIC ACID

A process for producing 2,3,4-trifluoro-5-(iodo or bromo)benzoic acid, the process comprising a haloganation step in which 2,3,4-trifluorobenzoic acid is iodinated or brominated directly with an iodinating agent or brominating agent in a reaction solvent

Extensive halogen scrambling and buttressing effects encountered upon treatment of oligobromoarenes with bases

As a rule, tri-, tetra- and pentahaloarenes readily undergo ortho-lithiation when treated with amide-type bases. However, halogen migration occurs whenever the substrate contains three or more contiguous halogen atoms, provided that at least one of them is bromine or iodine. Dismutation and reduction processes often take place concomitantly. In this manner, a variety of organometallic intermediates may be formed, the driving force always being a decrease in basicity. When no such energy gain can be achieved, a sterically crowded substrate may just turn out to be inert; this was found to be the case with 1,5-dibromo-3-fluoro-2-(trimethylsilyl)benzene, 1,5-dibromo-3-fluoro-2,4-bis(trimethylsilyl)benzene, and 1,5-dibromo-3-fluoro-2,4-diiodobenzene. Buttressing effects are apparently strong enough to prevent expedient deprotonation of those substrates.

Trifluoro-substituted benzoic acid, esters thereof, and process for producing the same

The present invention is to provide a trifluoro-substituted benzoic acid, an ester thereof, particularly 2,3,4-trifluoro-5-iodobenzoic acid, 2,3,4-trifluoro-5-trifluoromethylbenzoic acid, esters thereof, which are useful as a starting material for synthesizing a quinolonecarboxylic acid compound useful as a medicine, an anti-bacterial agent or an antiviral agent, and processes for preparing these compounds and 2,4,5-trifluoro-3-iodobenzoic acid, 2,4,5-trifluoro-3-trifluoromethylbenzoic acid and esters thereof.